Victory Square Technologies Reports a Record First Half 2020

In This Article:

Net income for the six-month period ending June 30 increased to $4,726,867 and earnings per share increased to $0.07

VANCOUVER, British Columbia, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Victory Square Technologies Inc. (“Victory Square'' or the “Company”) (CSE:VST) (OTC:VSQTF) (FWB:6F6), a company that builds and invests in cutting-edge technology that is shaping the 4th Industrial Revolution, announces it has filed its condensed interim consolidated financial statements and Interim Management Discussion and Analysis (MD&A) for the three months ended June 30, 2020.

Highlights for the six-month period ending June 30:

  • Net income increased to $4,726,867 from $(2,751,933) during the same period last year.

  • Earnings per share increased to $0.07 from $(0.03) during the same period last year.

  • 20+ portfolio companies that represent pillars of the future economy: digital health and diagnostics, artificial intelligence (AI), machine learning (ML), augmented and virtual reality (AR and VR), internet of things (IOT), cyber security, blockchain and more.

  • Portfolio company, Victory Square Health gets FDA Permission to Manufacture and Market Safetest Covid-19 Antibody Test in the United States and is the first to be approved by the São Paulo State Government Covid-19 Innovation Programme.

  • Portfolio company, FansUnite Entertainment Inc., raised $8,141,764 and listed on the Canadian Securities Exchange (“CSE”).

  • VST ended the quarter with a strong balance sheet with $1,683,991 in cash and cash equivalents. The Company also has access to a $10,000,000 convertible note for operational and growth capital.

The Company’s condensed interim consolidated financial statements and Interim MD&A for the three months ended June 30, 2020 are available under the Company’s profile on SEDAR (www.sedar.com).

A Note from the CEO of VST: A Record-Setting First Half 2020 and Look Ahead

Dear Fellow Shareholders,

I am excited to connect with all of you after another exceptional quarter for Victory Square Technologies (VST) and in the wake of important news. Last month, our portfolio company Victory Square Health, makers of a Covid-19 antibody test was granted permission by the FDA to commence marketing, sales and distribution. Test kits will be available to labs across the United States in the next several weeks. The Company was also approved in Brazil by the São Paulo State Government as part of its Covid-19 Innovation Program.

I’m extremely proud that we’ll be able to play a part in the fight against the pandemic and help accelerate testing to get people back to work and school. Importantly, this is not an overnight success. VST first identified Safetest’s potential in 2017 through a partnership in Brazil and worked hard to bring its technology to Canada.